Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-06-15
1995-10-31
Higel, Floyd D.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C07D40106, C07D40306, C07D40906, A61K 31415
Patent
active
054630746
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND
H.sub.3 receptor sites are known and are of current interest to those skilled in the art--for example, see: West, Jr. et al., "Biexponential Kinetics of (R)-.alpha.-[.sup.3 H)Methylhistamine Binding to the Rat Brain H.sub.3 Histamine Receptor", Journal of Neurochemistry, Vol. 55, No. 5, pp. 1612-1616, 1990; West, Jr. et al., "identification of Two H.sub.3 -Histamine Receptor Subtypes", Molecular Pharmacology, 38:610-613; and Korte et al., "Characterization and Tissue Distribution of H.sub.3 Histamine Receptors in Guinea Pigs by N.sup..alpha. -Methylhistamine", Biochemical and Biophysical Research Communications, Vol. 168, No. 3, pp. 9079-986.
Arrang et al. in U.S. Pat. No. 4,767,778 (issued Aug. 30, 1988) disclose a pharmaceutical composition containing a histamine derivative of the formula: ##STR2## wherein each of R.sub.1, R.sub.2, and R.sub.4, represents a hydrogen or a methyl, or R.sub.1 and R.sub.2 taken together represent a methylene, and R.sub.3 is a hydrogen, a methyl or a carboxy, with the proviso that R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are not simultaneously methyl groups. It is disclosed that the derivatives behave as complete agonists of the H.sub.3 receptors in rat brain and produce a maximum inhibition of release identical to that induced by histamine (approximately 60%). It is also disclosed that the histamine derivatives powerfully inhibit the release and synthesis of histamine by very selectively stimulating the H.sub.3 receptors. Consequently, according to Arrang et al., the derivatives are likely to decrease histaminergic transmission in the digestive tract and in the nervous, cardiovascular and immune systems. Arrang et al. disclose that the derivatives can be used in therapy as a drug having sedative effects, as a sleep regulator, anticonvulsant, regulator of hypothalamo-hypophyseal secretion, antidepressant, and modulator of cerebral circulation. According to Arrang et al., inhibition of the release of inflammation messengers in various allergic conditions (e.g., asthma) is expected to result from stimulation of the H.sub.3 receptors of the lung. It is further disclosed that the inhibition of release of gastric histamine is likely to exert antisecretory and antiulcerative effects. According to Arrang et al., modification of release of the messengers of immune responses is likely to modulate the latter responses.
EP 0 338 939 discloses compounds of the formula: ##STR3##
Derwent abstract 86-273706/42 for EP 0 197 840 discloses imidazole derivatives of the formula: ##STR4## wherein R.sub.1 is H, methyl or ethyl; R is H or R.sub.2 ; and R.sub.2 is 1-6C alkyl, piperonyl, 3-(benzimidazolon-1-yl)propyl, --CZ--NHR.sub.5 or a group (i): ##STR5## wherein n is 0--4; X is a bond, O, S, NH, CO, CH.dbd.CH or a group (ii): n n ##STR6## R.sub.3 is H, methyl, halo, CN, CF.sub.3 or COR.sub.4 ; R.sub.4 is 1-6C alkyl, 3-6C cycloalkyl or phenyl (optionally substituted by methyl or F); Z is O, S, NH, N-methyl or N--CN; and R.sub.5 is 1-8C alkyl, 3-6C cycloalkyl (optionally substituted by methyl, halo or CF.sub.3), phenyl(1-3C)alkyl, naphthyl, adamantyl or p-toluenesulphonyl. It is disclosed that these compounds are phychotropic agents. It is also disclosed that these compounds antagonise the histamine H3 receptors and increase the speed of cerebral histamine renewal.
Derwent abstract 90-184730/24 for U.S. Pat. No. 4,925,851 discloses 2- or 4-(2-(1H-imidazol-1-yl)ethyl) piperidine compounds useful as antitumour agents for inhibiting lymphoma, sarcoma, myeloma and leukaemia. The compounds have the formula: ##STR7## wherein R is --CH.sub.2 (CH.sub.2).sub.m --Me, --CO--(CH.sub.2).sub.m --Me or --CO--CMe.sub.2 --R.sub.2 ; m is 2-18; R.sub.2 is H or Me; R.sub.1 is --(CH.sub.2).sub.n --R.sub.3 ; n is 0-13; R.sub.3 is H, i-Pr or t-Bu; and the floating group is at the 2- or 4-position; with the proviso that (1) the sum of C atoms in R.sub.1 does not exceed 13; and (2) the sum of C atoms in R and R.sub.1 does not exceed 25.
Derwent abstract 90-180087/24 for EP 372125A discloses compounds of the formu
REFERENCES:
patent: 2987522 (1961-06-01), Shen
patent: 3470197 (1969-09-01), Van Dyke
patent: 3491098 (1970-02-01), Archer
patent: 4011238 (1977-03-01), Fontanella et al.
patent: 4259345 (1981-03-01), Cross et al.
patent: 4273782 (1981-06-01), Cross et al.
patent: 4404382 (1983-09-01), Gall
patent: 4404387 (1983-09-01), Gall
patent: 4416895 (1983-11-01), Thorogood
patent: 4431653 (1984-02-01), Wei et al.
patent: 4581370 (1986-04-01), Diamond et al.
patent: 4587239 (1986-05-01), Regel et al.
patent: 4767778 (1988-08-01), Arrang et al.
patent: 4925851 (1990-05-01), Houlihan
patent: 4935417 (1990-06-01), Pascal et al.
patent: 5010075 (1991-04-01), Pascal et al.
patent: 5021434 (1991-06-01), Strehlke et al.
patent: 5066663 (1991-11-01), Hobbs
patent: 5071859 (1991-12-01), Knudsen et al.
patent: 5091428 (1992-02-01), Pascal et al.
patent: 5264449 (1993-11-01), Albaugh
West Jr. et al., Journal of Neurochemistry, vol. 55, No. 5, pp. 1612-1616 (1990).
West Jr. et al, Molecular Pharmacology, 38:610-613 (1990).
Korte et al., Biochemical and Biophysical Research Communications, vol. 168, No. 3, pp. 979-986 (1990).
Derwent Abstract 86-273706/42 For EP 0197 840 (1986).
Derwent Abstract 90-184730/24 For US 4925851 (1990).
Derwent Abstract 90-180087/24 For EP 372125 (1990).
Derwent Abstract 88-309195/44 For US 4935417 (1988).
Derwent Abstract 89-237742/33 For JP 1172383 (1989).
Appel, Current Neurology, vol. 6, pp. 289g 313-316, (1987), ("Alzheimer's Disease").
Chemical Abstracts 80(15): 82801a (1973). Schumack.
CA 98 (23): 194919y (1983) Tchissambou et al.
CA 96(17): 139642m (1982) Waterman et al.
CA 106(11): 84602r (1987) Arrang et al. IV.
CA 89(13): 109229v (1978) DeGraw et al.
CA 89 (23): 197598t (1978) Malesct.
CA 72 (17): 90459v (1970) and CA 69 (3): 10467w (1968) Archer (1968).
RN 80101-09-3 For CA 96 (1): 6760b (1982) Bagli et al.
Aslanian Robert
Ganguly Ashit K.
Green Michael J.
Lupo, Jr. Andrew
Piwinski John J.
Higel Floyd D.
Jeanette Henry C.
Maitner John J.
Nelson James R.
Schering Corporation
LandOfFree
Imidazolyl or imidazoylalkyl substituted with a four or five mem does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolyl or imidazoylalkyl substituted with a four or five mem, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolyl or imidazoylalkyl substituted with a four or five mem will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1773416